Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Novo Nordisk plans to quickly launch the pill form of Wegovy but is expected to soon face competition from Eli Lilly.

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

FDA may expedite approval timeline for Eli Lilly's weight-loss treatment, potentially moving decision date to late March from ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Novo Nordisk receives FDA approval for its oral weight-loss pill. Analyst says NVO stock might now have an edge over Eli Lilly.

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much ...

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market ...